Immune Response to COVID-19 Vaccine in Multiple Sclerosis Patients Treated With Teriflunomide and Alemtuzumab

NCT05075499 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

70

Enrollment

OTHER_GOV

Sponsor class

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL: COVID-19 vaccination

Sponsor

Sheba Medical Center

Collaborators

[object Object]